Chang-Hyun Kim1, Chi-Yeon Lim2, Ju-Hee Lee3, Keun Cheon Kim4, Ji Yeon Ahn5, Eun Ju Lee6. 1. 1College of Medicine, Dongguk University, 32 Donggukro, Ilsandonggu, Goyang, Gyeonggi 10326 Republic of Korea. 2. 2Department of Biostatistics, Dongguk University, 32 Donggukro, Ilsandonggu, Goyang, Gyeonggi 10326 Republic of Korea. 3. 3College of Korean Medicine, Dongguk University, 123 Dongdaero, Gyeongju, Gyeongsangbuk 38066 Republic of Korea. 4. 4Department of Agricultural Biotechnology, Seoul National University, 1 Gwanak ro, Gwanakgu, Seoul, 08826 Republic of Korea. 5. 5Research Institute of Agriculture and Life Sciences, Seoul National University, 1 Gwanakro, Gwanakgu, Seoul, 08826 Republic of Korea. 6. 6Biomedical Research Institute, Seoul National University Hospital, 103 Daehakro, Jongnogu, Seoul, 03080 Republic of Korea.
Abstract
BACKGROUND: Mesenchymal stem cells (MSCs) can be used for a wide range of therapeutic applications because of not only their differentiation potential but also their ability to secrete bioactive factors. Recently, several studies have suggested the use of human embryonic stem cell-derived MSCs (hE-MSCs) as an alternative for regenerative cellular therapy due to mass production of MSCs from a single donor. METHODS: We generated hE-MSCs from embryonic stem cell lines, SNUhES3, and analyzed immune properties of these cells. Also, we evaluated the in-vivo therapeutic potential of hE-MSCs in immune-mediated inflammatory skin disease. RESULTS: The cell showed the suppression of immunity associated with allogenic peripheral blood mononuclear cells in mixed lymphocyte response assay. We also detected that cytokines and growth factor related to the immune response were secreted from these cells. To assessed the in-vivo therapeutic potential of hE-MSCs in immune-mediated inflammatory skin disease, we used imiquimod (IMQ)-induced skin psoriasis mouse model. The score of clinical skin was significantly reduced in the hE-MSCs treated group compared with control IMQ group. In histological analysis, the IMQ-induced epidermal thickness was significantly decreased by hE-MSCs treatment. It was correlated with splenomegaly induced by IMQ which was also improved in the hE-MSCs. Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-α, IFN-α, IFN-γ,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs. CONCLUSION: These results suggested that hE-MSCs have a potency of immune modulation in psoriasis, which might be the key factor for the improved psoriasis.
BACKGROUND: Mesenchymal stem cells (MSCs) can be used for a wide range of therapeutic applications because of not only their differentiation potential but also their ability to secrete bioactive factors. Recently, several studies have suggested the use of human embryonic stem cell-derived MSCs (hE-MSCs) as an alternative for regenerative cellular therapy due to mass production of MSCs from a single donor. METHODS: We generated hE-MSCs from embryonic stem cell lines, SNUhES3, and analyzed immune properties of these cells. Also, we evaluated the in-vivo therapeutic potential of hE-MSCs in immune-mediated inflammatory skin disease. RESULTS: The cell showed the suppression of immunity associated with allogenic peripheral blood mononuclear cells in mixed lymphocyte response assay. We also detected that cytokines and growth factor related to the immune response were secreted from these cells. To assessed the in-vivo therapeutic potential of hE-MSCs in immune-mediated inflammatory skin disease, we used imiquimod (IMQ)-induced skin psoriasis mouse model. The score of clinical skin was significantly reduced in the hE-MSCs treated group compared with control IMQ group. In histological analysis, the IMQ-induced epidermal thickness was significantly decreased by hE-MSCs treatment. It was correlated with splenomegaly induced by IMQ which was also improved in the hE-MSCs. Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-α, IFN-α, IFN-γ,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs. CONCLUSION: These results suggested that hE-MSCs have a potency of immune modulation in psoriasis, which might be the key factor for the improved psoriasis.
Authors: Eun Ju Lee; Eue-Keun Choi; Soo Kyoung Kang; Gi-Hwan Kim; Ju Young Park; Hyun-Jae Kang; Sae-Won Lee; Keum-Hyun Kim; Jin Sook Kwon; Ki Hong Lee; Youngkeun Ahn; Ho-Jae Lee; Hyun-Jai Cho; Soo Jin Choi; Won Il Oh; Young-Bae Park; Hyo-Soo Kim Journal: Mol Ther Date: 2011-11-08 Impact factor: 11.454
Authors: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan Journal: J Am Acad Dermatol Date: 2009-06-03 Impact factor: 11.527
Authors: Leslie van der Fits; Sabine Mourits; Jane S A Voerman; Marius Kant; Louis Boon; Jon D Laman; Ferry Cornelissen; Anne-Marie Mus; Edwin Florencia; Errol P Prens; Erik Lubberts Journal: J Immunol Date: 2009-05-01 Impact factor: 5.422
Authors: Soon Hee Kim; Ji Hoon Park; Jin Seon Kwon; Jae Gu Cho; Kate G Park; Chan Hum Park; James J Yoo; Anthony Atala; Hak Soo Choi; Moon Suk Kim; Sang Jin Lee Journal: Biomaterials Date: 2020-08-06 Impact factor: 12.479
Authors: Ji Suk Choi; Min Sang Lee; Jooyoung Kim; Min Rye Eom; Eun Ji Jeong; Minhyung Lee; Su A Park; Ji Hoon Jeong; Seong Keun Kwon Journal: Tissue Eng Regen Med Date: 2021-03-25 Impact factor: 4.169
Authors: Dan Xing; Kai Wang; Jun Wu; Yu Zhao; Wei Liu; Jiao Jiao Li; Tingting Gao; Deng Yan; Liu Wang; Jie Hao; Jianhao Lin Journal: Molecules Date: 2021-01-24 Impact factor: 4.411